Time on therapy and concomitant medication use of mepolizumab in Canada: a retrospective cohort study

About half of the patients who initiate therapy with mepolizumab discontinue treatment within the first or second year. Concomitant use of short-acting β(2)-agonists and oral corticosteroids drops during mepolizumab use. https://bit.ly/3aRISqS

Detalles Bibliográficos
Autores principales: Lee, Jason K., Gendron, Alain, Knutson, Michelle, Sriskandarajah, Niroshan, Mbuagbaw, Lawrence, Noorduyn, Stephen G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2021
Materias:
Original Research Letters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8005685/
https://www.ncbi.nlm.nih.gov/pubmed/33816603
http://dx.doi.org/10.1183/23120541.00778-2020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8005685/
https://www.ncbi.nlm.nih.gov/pubmed/33816603
http://dx.doi.org/10.1183/23120541.00778-2020

Ejemplares similares